MX2009009843A - Compuestos espiro sustituidos como inhibidores de la angiogenesis. - Google Patents
Compuestos espiro sustituidos como inhibidores de la angiogenesis.Info
- Publication number
- MX2009009843A MX2009009843A MX2009009843A MX2009009843A MX2009009843A MX 2009009843 A MX2009009843 A MX 2009009843A MX 2009009843 A MX2009009843 A MX 2009009843A MX 2009009843 A MX2009009843 A MX 2009009843A MX 2009009843 A MX2009009843 A MX 2009009843A
- Authority
- MX
- Mexico
- Prior art keywords
- angiogenesis inhibitors
- substituted compounds
- spiro
- tyrosine kinases
- spiro substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La presente invención se refiere a compuestos espiro (tetracarburo) sustituidos de fórmula I, procedimientos para su preparación, composiciones farmacéuticas que los contienen como ingrediente activo, métodos de tratamiento de enfermedades asociadas con la angiogénesis, tales como cáncer asociado con tirosina cinasas de proteína, y a su uso como medicamentos para la inhibición de los efectos reductores de tirosina cinasas en animales de sangre caliente, tales como humanos. (ver fórmula I).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89469307P | 2007-03-14 | 2007-03-14 | |
| US94169907P | 2007-06-04 | 2007-06-04 | |
| US12/036,245 US8163923B2 (en) | 2007-03-14 | 2008-02-23 | Spiro substituted compounds as angiogenesis inhibitors |
| PCT/US2008/054817 WO2008112408A1 (en) | 2007-03-14 | 2008-02-24 | Spiro substituted compounds as angiogenesis inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009009843A true MX2009009843A (es) | 2009-09-24 |
Family
ID=39759894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009009843A MX2009009843A (es) | 2007-03-14 | 2008-02-24 | Compuestos espiro sustituidos como inhibidores de la angiogenesis. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8163923B2 (es) |
| EP (1) | EP2125777B1 (es) |
| JP (1) | JP5441722B2 (es) |
| KR (2) | KR20150039889A (es) |
| CN (1) | CN101558055B (es) |
| AU (1) | AU2008226667B2 (es) |
| BR (1) | BRPI0808764B8 (es) |
| CA (1) | CA2681005C (es) |
| CY (1) | CY1114092T1 (es) |
| DK (1) | DK2125777T3 (es) |
| ES (1) | ES2416711T3 (es) |
| HR (1) | HRP20130633T1 (es) |
| IL (1) | IL200854A (es) |
| ME (1) | ME02323B (es) |
| MX (1) | MX2009009843A (es) |
| NZ (1) | NZ579619A (es) |
| PL (1) | PL2125777T3 (es) |
| PT (1) | PT2125777E (es) |
| RS (1) | RS52853B (es) |
| SI (1) | SI2125777T1 (es) |
| WO (1) | WO2008112408A1 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8163923B2 (en) * | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| US8148532B2 (en) * | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| AU2009303602B2 (en) * | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| IT1393351B1 (it) * | 2009-03-16 | 2012-04-20 | Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa | Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi |
| EP2423208A1 (en) * | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| US8664244B2 (en) | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| AU2012225735B2 (en) | 2011-03-04 | 2016-03-10 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| RU2015127211A (ru) * | 2013-01-18 | 2017-03-03 | Адвенчен Фармасьютикалс, Ллс | Способ получения противоопухолевого агента 6-(7-((1-аминоциклопропил) метокси)-6-метоксихинолин-4-илокси)-n-метил-1-нафтамида и его кристаллической структуры |
| ES2654100T3 (es) | 2013-02-21 | 2018-02-12 | Glaxosmithkline Intellectual Property Development Limited | Quinazolinas como inhibidores de quinasa |
| FR3009497B1 (fr) * | 2013-08-09 | 2015-08-07 | Servier Lab | Nouvelle association entre le 6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolein-4-yl}oxy)-n-methylnaphtalene-1-carboxamide et un anti-oestrogene dans le cancer du sein |
| HUE053654T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére |
| CN105311029A (zh) | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
| CN105311030B (zh) | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
| CA2954999C (en) | 2014-07-14 | 2020-01-07 | Advenchen Pharmaceuticals, Nanjing Ltd. | Fused quinoline compounds as pi3k, mtor inhibitors |
| KR20220162823A (ko) | 2014-09-26 | 2022-12-08 | 얀센 파마슈티카 엔.브이. | Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용 |
| CN107001326B (zh) | 2014-12-09 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 抗非小细胞肺癌的喹啉衍生物 |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| US9751859B2 (en) | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
| CN108601773A (zh) | 2015-07-11 | 2018-09-28 | 南京爱德程医药科技有限公司 | 作为pi3k/mtor抑制剂的稠合喹啉化合物 |
| CN106543143B (zh) * | 2015-09-22 | 2019-03-22 | 合肥中科普瑞昇生物医药科技有限公司 | 一类新型的flt3激酶抑制剂及其用途 |
| AU2016333987A1 (en) | 2015-10-05 | 2018-05-10 | Ny State Psychiatric Institute | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies |
| CN107296811B (zh) | 2016-04-15 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 一种用于治疗胃癌的喹啉衍生物 |
| JOP20190280A1 (ar) | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| EP3766870B1 (en) | 2018-03-02 | 2023-09-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal of compound as c-met kinase inhibitor and preparation method therefor and use thereof |
| CN110483393A (zh) * | 2018-05-14 | 2019-11-22 | 上海海和药物研究开发有限公司 | 德立替尼的晶型 |
| CN110551065B (zh) * | 2018-06-01 | 2021-02-26 | 海创药业股份有限公司 | 氘代Lucitanib化合物及其用途 |
| JP2022501355A (ja) | 2018-09-21 | 2022-01-06 | ヤンセン ファーマシューティカ エヌ．ベー． | 胆管癌の処置 |
| CN113195000A (zh) | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | 抗体-药物缀合物和激酶抑制剂的组合 |
| BR112021019446A2 (pt) | 2019-03-29 | 2021-11-30 | Janssen Pharmaceutica Nv | Inibidores de tirosina quinase fgfr para o tratamento de carcinoma urotelial |
| JOP20210260A1 (ar) | 2019-03-29 | 2023-01-30 | Janssen Pharmaceutica Nv | مثبطات كيناز تيروسين مستقبل عامل نمو الأرومة الليفية لمعالجة كارسينوما الظهارة البولية |
| CN112778217B (zh) * | 2019-11-08 | 2024-01-26 | 沈阳化工研究院有限公司 | 一种喹唑啉类化合物及其应用 |
| AU2021220285A1 (en) | 2020-02-12 | 2022-10-06 | Janssen Pharmaceutica Nv | FGFR tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
| TW202140012A (zh) | 2020-02-12 | 2021-11-01 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑 |
| AU2021339962A1 (en) | 2020-09-14 | 2023-05-25 | Janssen Pharmaceutica Nv | Fgfr inhibitor combination therapies |
| CN115227675A (zh) * | 2021-04-22 | 2022-10-25 | 南京爱德程医药科技有限公司 | 一种含有德立替尼的药物组合物 |
| KR20240009465A (ko) | 2021-05-19 | 2024-01-22 | 얀센 파마슈티카 엔브이 | 진행성 고형 종양의 치료를 위한 fgfr 티로신 키나제 억제제 |
| WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| WO2023228095A1 (en) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
| CN115160221A (zh) * | 2022-07-26 | 2022-10-11 | 上海歆贻医药科技有限公司 | 德立替尼晶型化合物和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2004018430A1 (ja) | 2002-08-23 | 2005-12-08 | 麒麟麦酒株式会社 | ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
| JP2007510708A (ja) | 2003-11-06 | 2007-04-26 | ファイザー・プロダクツ・インク | 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ |
| BRPI0418102A (pt) | 2003-12-23 | 2007-04-27 | Pfizer | derivados de quinolina |
| WO2005073224A2 (en) | 2004-01-23 | 2005-08-11 | Amgen Inc | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| US8148532B2 (en) * | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| US8163923B2 (en) * | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
-
2008
- 2008-02-23 US US12/036,245 patent/US8163923B2/en active Active
- 2008-02-24 CA CA2681005A patent/CA2681005C/en active Active
- 2008-02-24 SI SI200830992T patent/SI2125777T1/sl unknown
- 2008-02-24 WO PCT/US2008/054817 patent/WO2008112408A1/en active Application Filing
- 2008-02-24 JP JP2009553673A patent/JP5441722B2/ja active Active
- 2008-02-24 KR KR20157008029A patent/KR20150039889A/ko not_active Application Discontinuation
- 2008-02-24 CN CN200880000747.XA patent/CN101558055B/zh active Active
- 2008-02-24 ME MEP-2016-17A patent/ME02323B/me unknown
- 2008-02-24 NZ NZ579619A patent/NZ579619A/en unknown
- 2008-02-24 KR KR1020097019020A patent/KR101540421B1/ko active IP Right Grant
- 2008-02-24 MX MX2009009843A patent/MX2009009843A/es active IP Right Grant
- 2008-02-24 DK DK08730590.0T patent/DK2125777T3/da active
- 2008-02-24 ES ES08730590T patent/ES2416711T3/es active Active
- 2008-02-24 EP EP08730590.0A patent/EP2125777B1/en active Active
- 2008-02-24 PL PL08730590T patent/PL2125777T3/pl unknown
- 2008-02-24 PT PT87305900T patent/PT2125777E/pt unknown
- 2008-02-24 BR BRPI0808764A patent/BRPI0808764B8/pt active IP Right Grant
- 2008-02-24 AU AU2008226667A patent/AU2008226667B2/en active Active
- 2008-02-24 RS RS20130286A patent/RS52853B/en unknown
-
2009
- 2009-09-10 IL IL200854A patent/IL200854A/en active IP Right Grant
-
2012
- 2012-03-05 US US13/411,874 patent/US8513283B2/en active Active
-
2013
- 2013-06-28 CY CY20131100526T patent/CY1114092T1/el unknown
- 2013-07-05 HR HRP20130633AT patent/HRP20130633T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009008953A (es) | Compuestos como inhibidores de angiogenesis. | |
| MX2009009843A (es) | Compuestos espiro sustituidos como inhibidores de la angiogenesis. | |
| AU2009282962A8 (en) | Compounds as kinase inhibitors | |
| WO2012034055A3 (en) | Compounds as c-met kinase inhibitors | |
| MX2009004699A (es) | Compuestos de piridinona. | |
| EA201000552A1 (ru) | Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в | |
| GEP20156285B (en) | Compounds and compositions as trk inhibitors | |
| WO2008145688A3 (en) | Pyrrolopyridine compounds, process for their preparation, and their use as medicaments | |
| MX2010014057A (es) | Compuestos de piridina. | |
| MX2009002171A (es) | Derivados de triazol como inhibidores de cinasas. | |
| MX2013008296A (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
| EP1973407A4 (en) | SPIRO COMPOUNDS AND METHODS OF USE | |
| GEP20166484B (en) | Protein kinase inhibitors | |
| MX2011012337A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades. | |
| MX2009012066A (es) | Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k. | |
| WO2009132774A8 (en) | New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors | |
| EA201100503A1 (ru) | Глюкозидные производные и их применения | |
| EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
| IN2012DN01453A (es) | ||
| MX2012001838A (es) | Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion. | |
| MX2009004745A (es) | Derivados de 1,2,3-triazol como inhibidores del receptor sigma. | |
| MX2010013682A (es) | Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos. | |
| MX2009009153A (es) | Pirano-pirazol-aminas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |